AI assistant
Wave Life Sciences Ltd. — Director's Dealing 2024
Aug 15, 2024
31900_dirs_2024-08-14_890fc020-77c8-423d-b7ee-527d1bf2bd1b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Wave Life Sciences Ltd. (WVE)
CIK: 0001631574
Period of Report: 2024-08-12
Reporting Person: Wagner Heidi L (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-08-12 | Ordinary Shares | A | 32230 | $0.00 | Acquired | 32230 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-08-12 | Share Option (right to buy) | $5.37 | A | 64460 | Acquired | 2029-08-12 | Ordinary Shares (64460) | Direct |
Footnotes
F1: The reporting person was granted this restricted share unit award (RSU) pursuant to the 2024 Non-Employee Director Compensation Policy. The RSU vests as to 50% on each of (i) the earlier of the Company's 2025 annual general meeting or August 12, 2025; and (ii) the earlier of the Company's 2026 annual general meeting or August 12, 2026.
F2: The reporting person was granted this option pursuant to the 2024 Non-Employee Director Compensation Policy. The option vests as to 12.5% on a quarterly basis beginning August 12, 2024, through the two-year period following the grant date.